All News #Library
Rare Diseases
Theravance Biopharma Misses Phase 3 CYPRESS Goal, Cuts Costs
03 Mar 2026 //
PR NEWSWIRE
Theravance Bio Completes Enrollment in Pivotal Ph 3 CYPRESS Study
25 Aug 2025 //
PR NEWSWIRE
Theravance Biopharma to Present Ampreloxetine at MSA Congress
09 May 2025 //
PR NEWSWIRE
Theravance Biopharma Announces Orphan Drug Designation Granted to Ampreloxetine
09 May 2023 //
PR NEWSWIRE

Market Place
Sourcing Support